Visual metrics in BD Multi-Omics: Your key to finding the impossible!

It has always been difficult to find the impossible, but what makes it so?

To unravel the secrets of single-cells it is important to start the experiment with viable and live cells. The BD Multi-Omics workflow enables this using visual metrics, providing you with accurate information about cell counts and viability along the entire process. This is made possible by the scanner of the BD Rhapsody™ Single-Cell Analysis System, which provides measures like cell-capture rate and cell-multiplet rate through direct imaging at different stages of the workflow.

The simultaneous assessment of both protein and mRNA expression in a single experiment using the BD Rhapsody™ Single-Cell Analysis System and the BD® AbSeq oligo-conjugated antibodies makes it possible to address more new questions in single-cell biology than ever before. Coupled with the BD FACSMelody™ Cell Sorter, the BD Multi_Omics workflow opens new vistas in biology that were, so far, in the realm of the impossible.

Motivated to find the impossible now?

Visit our dedicated website that will help you get started

Do you wish to gain access to incredible single-cell Multi-Omics technologies?

Visit this page to learn how

BD, the BD Logo, FACSMelody™ and Rhapsody™ are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners © 2021 BD. All rights reserved.
Products are for Research Use Only. Not for use in diagnostic or therapeutic procedures.
BD FACSMelody is a Class 1 Laser Product

Newsletter

Do not miss any essential information join us :)

Send me the Flowcytometry News newsletter. I expressly agree to receive the newsletter and know that I can easily unsubscribe at any time.

Stay up to date on what happens in Flowcytometry News !

Register and receive our newsletter each month

Send me the Flowcytometry News newsletter. I expressly agree to receive the newsletter and know that I can easily unsubscribe at any time.